DaVita Inc. (NYSE:DVA) CEO Sells $1,609,120.85 in Stock

DaVita Inc. (NYSE:DVA) CEO Javier Rodriguez sold 9,881 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the sale, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at $144,583,929.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Javier Rodriguez also recently made the following trade(s):

• On Monday, September 16th, Javier Rodriguez sold 50,000 shares of DaVita stock. The stock was sold at an average price of $165.05, for a total value of $8,252,500.00.
• On Monday, August 26th, Javier Rodriguez sold 32,176 shares of DaVita stock. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68.

DaVita Stock Down 0.6 %

Shares of DVA traded down $1.00 during midday trading on Tuesday, hitting $164.19. The company had a trading volume of 882,594 shares, compared to its average volume of 821,344. The stock has a market cap of $13.78 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.90 and a beta of 0.87. The company’s 50 day moving average price is $145.73 and its 200 day moving average price is $140.27. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $166.04.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a return on equity of 77.00% and a net margin of 6.86%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.15 billion. During the same period in the previous year, the company earned $2.08 earnings per share. DaVita’s quarterly revenue was up 6.2% on a year-over-year basis. On average, equities research analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

Institutional Investors Weigh In On DaVita

Several institutional investors and hedge funds have recently made changes to their positions in DVA. Vanguard Group Inc. increased its stake in DaVita by 2.4% during the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock valued at $662,161,000 after purchasing an additional 145,711 shares during the last quarter. Gates Capital Management Inc. lifted its holdings in DaVita by 3.1% in the fourth quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after acquiring an additional 27,660 shares during the last quarter. 8 Knots Management LLC acquired a new position in DaVita in the fourth quarter valued at approximately $89,504,000. Allianz Asset Management GmbH raised its position in shares of DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after purchasing an additional 213,992 shares during the period. Finally, Doma Perpetual Capital Management LLC acquired a new stake in shares of DaVita during the 4th quarter worth approximately $53,076,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. UBS Group boosted their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen raised their target price on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Truist Financial increased their price target on DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.